drugset / Trial / NCT01156753
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This study will also further characterize the safety of CDX-011 treatment in this patient population.
Timeline
- Start
- 2010-07
- Primary completion
- 2012-10
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Eribulin | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Glembatumumab Vedotin | Other / unclassified | 1.88 mg/kg | Intravenous |
| Subject | Ixabepilone | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Vinorelbine | Small molecule | — | — |